Disease spectrum and pathogenic genes of inherited metabolic disorder in Gansu Province of China
ZHANG Chuan, HUI Ling, ZHOU Bing-Bo, ZHENG Lei, WANG Yu-Pei, HAO Sheng-Ju, DA Zhen-Qiang, MA Ying, GUO Jin-Xian, CAO Zong-Fu, MA Xu
National Research Institute for Health and Family Planning/National Human Genetic Resources Center, Beijing 100081, China (Cao Z-F, Email: zongfu_cao@163.com)
Abstract：Objective To investigate the disease spectrum and pathogenic genes of inherited metabolic disorder (IMD) among neonates in Gansu Province of China. Methods A retrospective analysis was conducted on the tandem mass spectrometry data of 286 682 neonates who received IMD screening in Gansu Provincial Maternal and Child Health Hospital from January 2018 to December 2021. A genetic analysis was conducted on the neonates with positive results in tandem mass spectrometry during primary screening and reexamination. Results A total of 23 types of IMD caused by 28 pathogenic genes were found in the 286 682 neonates, and the overall prevalence rate of IMD was 0.63‰ (1/1 593), among which phenylketonuria showed the highest prevalence rate of 0.32‰ (1/3 083), followed by methylmalonic acidemia (0.11‰, 1/8 959) and tetrahydrobiopterin deficiency (0.06‰, 1/15 927). In this study, 166 variants were identified in the 28 pathogenic genes, with 13 novel variants found in 9 genes. According to American College of Medical Genetics and Genomics guidelines, 5 novel variants were classified as pathogenic variants, 7 were classified as likely pathogenic variants, and 1 was classified as the variant of uncertain significance. Conclusions This study enriches the database of pathogenic gene variants for IMD and provides basic data for establishing an accurate screening and diagnosis system for IMD in this region.
ZHANG Chuan,HUI Ling,ZHOU Bing-Bo et al. Disease spectrum and pathogenic genes of inherited metabolic disorder in Gansu Province of China[J]. CJCP, 2024, 26(1): 67-71.
El-Hattab AW, Almannai M, Sutton VR. Newborn screening: history, current status, and future directions[J]. Pediatr Clin North Am, 2018, 65(2): 389-405. PMID: 29502920. DOI: 10.1016/j.pcl.2017.11.013.
Almannai M, Marom R, Sutton VR. Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing[J]. Curr Opin Pediatr, 2016, 28(6): 694-699. PMID: 27552071. DOI: 10.1097/MOP.0000000000000414.
Grosse SD. Does newborn screening save money? The difference between cost-effective and cost-saving interventions[J]. J Pediatr, 2005, 146(2): 168-170. PMID: 15689900. DOI: 10.1016/j.jpeds.2004.10.015.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. PMID: 25741868. PMCID: PMC4544753. DOI: 10.1038/gim.2015.30.
American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system—executive summary[J]. Pediatrics, 2006, 117(5 Pt 2): S296-S307. PMID: 16735256. DOI: 10.1542/peds.2005-2633I.
Pena LD, van Calcar SC, Hansen J, et al. Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database[J]. Mol Genet Metab, 2016, 118(4): 272-281. PMID: 27209629. PMCID: PMC4970910. DOI: 10.1016/j.ymgme.2016.05.007.
Posset R, Garcia-Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders[J]. J Inherit Metab Dis, 2016, 39(5): 661-672. PMID: 27106216. DOI: 10.1007/s10545-016-9938-9.
Carleton SM, Peck DS, Grasela J, et al. DNA carrier testing and newborn screening for maple syrup urine disease in Old Order Mennonite communities[J]. Genet Test Mol Biomarkers, 2010, 14(2): 205-208. PMID: 20136525. PMCID: PMC5586154. DOI: 10.1089/gtmb.2009.0107.
